ARTICLE | Regulation
Biosimilars do-over
Why FDA withdrew draft biosimilar guidance
June 29, 2018 5:50 PM UTC
As part of an initiative to stimulate biosimilar competition, FDA is planning a do-over of draft guidance on statistical methods for demonstrating biosimilarity to a reference product.
The agency announced on June 21 it was withdrawing a draft guidance on statistical approaches for evaluating analytical similarities between a proposed biosimilar and its reference product. The withdrawal will be followed this month by an FDA biosimilars action plan that is intended to reduce the cost and uncertainty of developing products that compete with some of the most expensive medicines. ...